Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Hyuck Moon Kwon 2 Articles
Erratum: Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
Kwan Yong Lee, Dong Il Shin, Sung Ho Her, Seung Hwan Han, Youngkeun Ahn, Dong-Soo Kim, Dong-Ju Choi, Hyuck Moon Kwon, Hyeon-Cheol Gwon, Seung-Woon Rha, Sang-Ho Jo, Sung Cil Lim, Jun-Pyo Myong, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2020;2(1):31.   Published online January 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e1
Corrects: Cardiovasc Prev Pharmacother 2019;1(1):30
  • 2,032 View
  • 16 Download
PDF
Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
Kwan Yong Lee, Dong Il Shin, Sung Ho Her, Seung Hwan Han, Youngkeun Ahn, Dong-Soo Kim, Dong-Ju Choi, Hyuck Moon Kwon, Hyeon-Cheol Gwon, Seung-Woon Rha, Sang-Ho Jo, Sung Cil Lim, Jun-Pyo Myong, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2019;1(1):30-42.   Published online July 31, 2019
DOI: https://doi.org/10.36011/cpp.2019.1.e4
Correction in: Cardiovasc Prev Pharmacother 2020;2(1):31
  • 3,864 View
  • 15 Download
  • 2 Citations
Abstract PDF
Background
The aim of this multi-center prospective registry study was to evaluate the clinical efficacy of low-dose aspirin in vasospastic angina (VA) patients for the prevention of future cardiovascular events.
Methods
A total of 1,717 patients with positive and intermediate results of an intracoronary ergonovine provocation test in the VA in Korea registry (n=2,960) were classified into 100 mg/day aspirin intake (aspirin, n=743) and no-aspirin intake (control, n=974) groups. The primary end-point was a composite of major adverse cardiac events (MACEs) including cardiac death, new-onset arrhythmia, and acute coronary syndrome.
Results
The median follow-up duration was 2.0 years (25–75th, interquartile range 0.9–3.0 years). Cumulative composite MACE in the propensity score matched-pair cohort (n=1,028) was 3.6%. There was no significant difference in composite MACE between the aspirin and control groups (3.1% vs. 4.1%; hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.61–2.26; p=0.623). A sensitivity analysis of only the VA-positive population showed these results to be consistent. Even for patients with minimal organic stenosis (n=369), aspirin usage was not related to the incidence of a composite MACE (HR, 1.61; 95% CI, 0.55–4.72; p=0.380).
Conclusions
Low-dose aspirin does not protect against future cardiovascular events in VA patients, even patients who combine with minimal coronary artery stenosis.

Citations

Citations to this article as recorded by  
  • Characteristics of Patients with Vasospastic Angina in Korea: Data from a Large Cohort (VA-KOREA)
    Sung Eun Kim, Sang-Ho Jo, Won-Woo Seo, Min-Ho Lee, Hyun-Jin Kim, Seong-Sik Cho, Kwan Yong Lee, Dong-Soo Kim, Tae-Hyun Yang, Sung-Ho Her, Seung Hwan Han, Byoung-Kwon Lee, Youngkeun Ahn, Seung-Woon Rha, Hyeon-Cheol Gwon, Dong-Ju Choi, Sang Hong Baek
    Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 47.     CrossRef
  • Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
    Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
    Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1.     CrossRef

CPP : Cardiovascular Prevention and Pharmacotherapy
TOP